Bratislava, Slovakia - MultiplexDX, a leading biotechnology company, has announced the successful completion of its EIC Accelerator Project Multiplex8+.
The project was launched in 2019 and aimed to develop a ground-breaking technology that enables highly accurate breast cancer diagnostic test for effective personalized treatment and assessment of therapy response.
Throughout the project, MultiplexDX has made significant progress in developing the Multiplex8+ technology. The test combines two patented multiplexed cancer diagnostic technologies: visualization (RNA FISH) and RNA sequencing. MultiplexDX‘s IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization, and gene expression with a single-cell resolution by combining our proprietary visual and sequencing technologies into one diagnostic test.
"We are thrilled to announce the successful completion of the Multiplex8+ project," said Dr. Pavol Čekan, CEO of MultiplexDX. "Our team has worked tirelessly over the past four years to develop a technology that can potentially transform breast cancer diagnostics. With the precision ofMultiplex8+, we will save time, reduce costs, and provide greater accuracy to save patients' lives."
The Multiplex8+ project was funded by the European Innovation Council(EIC) Accelerator program, which supports high-risk, high-potential companies to scale up and bring innovative products and services to market. MultiplexDX was one of the few companies selected for the highly competitive program.
"We are grateful for the support of the EIC Accelerator program, which has been a fundamental part in helping us bring this technology to the next development stage," added Dr. Čekan. "We look forward to continuing to work with our partners and collaborators to bring the Multiplex8+ technology to the patients and healthcare providers who need it most."
MultiplexDX plans to commercialize the Multiplex8+ technology in the upcoming months and to significantly impact the field of breast cancer diagnostics.
For more information, please click here.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
